Activation of the DNA damage response is a conserved function of HIV-1 and HIV-2 Vpr that is independent of SLX4 recruitment

mBio

Volumn 7, Issue 5, 2016, Pages

  Fregoso, Oliver I ^a,b   Emerman, Michael ^a  

^a USA   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CELL PROTEIN; ENDONUCLEASE; SLX4 PROTEIN; UNCLASSIFIED DRUG; VPR PROTEIN; RECOMBINASE; SLX4 PROTEIN, HUMAN; VPR PROTEIN, HUMAN IMMUNODEFICIENCY VIRUS 1; VPR PROTEIN, HUMAN IMMUNODEFICIENCY VIRUS 2;

ARTICLE; CELL CYCLE ARREST; CONTROLLED STUDY; CORRELATION ANALYSIS; CRISPR CAS SYSTEM; DNA DAMAGE RESPONSE; GENE SILENCING; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS 2; NONHUMAN; PRIORITY JOURNAL; PROTEIN FUNCTION; PROTEIN PROTEIN INTERACTION; SLX4 GENE; SPECIES DIFFERENCE; VIRUS CELL INTERACTION; VIRUS REPLICATION; CELL CYCLE CHECKPOINT; CELL LINE; DNA DAMAGE; GENE INACTIVATION; GENETICS; HOST PATHOGEN INTERACTION; METABOLISM; PHYSIOLOGY;

CELL CYCLE CHECKPOINTS; CELL LINE; DNA DAMAGE; GENE KNOCKOUT TECHNIQUES; HIV-1; HIV-2; HOST-PATHOGEN INTERACTIONS; HUMANS; RECOMBINASES; VPR GENE PRODUCTS, HUMAN IMMUNODEFICIENCY VIRUS;

EID: 84994434538     PISSN: 21612129     EISSN: 21507511     Source Type: Journal    
DOI: 10.1128/mBio.01433-16     Document Type: Article

References (52)

1. Malim MH, Emerman M. 2008. HIV-1 accessory proteinsensuring viral survival in a hostile environment. Cell Host Microbe 3:388-398. http://dx.doi.org/10.1016/j.chom.2008.04.008
2. Lim ES, Fregoso OI, McCoy CO, Matsen FA, Malik HS, Emerman M. 2012. The ability of primate lentiviruses to degrade the monocyte restriction factor SAMHD1 preceded the birth of the viral accessory protein Vpx. Cell Host Microbe 11:194-204. http://dx.doi.org/10.1016/j.chom.2012.01.004
3. Tristem M, Purvis A, Quicke DL. 1998. Complex evolutionary history of primate lentiviral vpr genes. Virology 240:232-237. http://dx.doi.org/10.1006/viro.1997.8929
4. Beaumont T, van Nuenen A, Broersen S, Blattner WA, Lukashov VV, Schuitemaker H. 2001. Reversal of human immunodeficiency virus type 1 IIIB to a neutralization-resistant phenotype in an accidentally infected laboratory worker with a progressive clinical course. J Virol 75: 2246-2252. http://dx.doi.org/10.1128/JVI.75.5.2246-2252.2001
5. Campbell BJ, Hirsch VM. 1997. Vpr of simian immunodeficiency virus of African green monkeys is required for replication in macaque macrophages and lymphocytes. J Virol 71:5593-5602
6. Lang SM, Weeger M, Stahl-Hennig C, Coulibaly C, Hunsmann G, Müller J, Müller-Hermelink H, Fuchs D, Wachter H, Daniel MM, Desrosiers RC, Fleckenstein B. 1993. Importance of vpr for infection of rhesus monkeys with simian immunodeficiency virus. J Virol 67:902-912
7. Somasundaran M, Sharkey M, Brichacek B, Luzuriaga K, Emerman M, Sullivan JL, Stevenson M. 2002. Evidence for a cytopathogenicity determinant in HIV-1 Vpr. Proc Natl Acad Sci U S A 99:9503-9508. http://dx.doi.org/10.1073/pnas.142313699
8. Andersen JL, Planelles V. 2005. The role of Vpr in HIV-1 pathogenesis. Curr HIV Res 3:43-51. http://dx.doi.org/10.2174/1570162052772988
9. Lai M, Zimmerman ES, Planelles V, Chen J. 2005. Activation of the ATR pathway by human immunodeficiency virus type 1 Vpr involves its direct binding to chromatin in vivo. J Virol 79:15443-15451. http://dx.doi.org/10.1128/JVI.79.24.15443-15451.2005
10. Roshal M, Kim B, Zhu Y, Nghiem P, Planelles V. 2003. Activation of the ATR-mediated DNA damage response by the HIV-1 viral protein R. J Biol Chem 278:25879-25886. http://dx.doi.org/10.1074/jbc.M303948200
11. Zimmerman ES, Sherman MP, Blackett JL, Neidleman JA, Kreis C, Mundt P, Williams SA, Warmerdam M, Kahn J, Hecht FM, Grant RM, de Noronha CM, Weyrich AS, Greene WC, Planelles V. 2006. Human immunodeficiency virus type 1 Vpr induces DNA replication stress in vitro and in vivo. J Virol 80:10407-10418. http://dx.doi.org/10.1128/JVI.01212-06
12. Belzile JP, Abrahamyan LG, Gérard FC, Rougeau N, Cohen EA. 2010. Formation of mobile chromatin-associated nuclear foci containing HIV-1 Vpr and VPRBP is critical for the induction of G2 cell cycle arrest. PLoS Pathog 6:e1001080. http://dx.doi.org/10.1371/journal.ppat.1001080
13. Zimmerman ES, Chen J, Andersen JL, Ardon O, Dehart JL, Blackett J, Choudhary SK, Camerini D, Nghiem P, Planelles V. 2004. Human immunodeficiency virus type 1 Vpr-mediated G2 arrest requires Rad17 and Hus1 and induces nuclear BRCA1 and gamma-H2AX focus formation. Mol Cell Biol 24:9286-9294. http://dx.doi.org/10.1128/MCB.24.21.9286-9294.2004
14. Laguette N, Brégnard C, Hue P, Basbous J, Yatim A, Larroque M, Kirchhoff F, Constantinou A, Sobhian B, Benkirane M. 2014. Premature activation of the SLX4 complex by Vpr promotes G2/M arrest and escape from innate immune sensing. Cell 156:134-145. http://dx.doi.org/10.1016/j.cell.2013.12.011
15. Belzile JP, Duisit G, Rougeau N, Mercier J, Finzi A, Cohen EA. 2007. HIV-1 Vpr-mediated G2 arrest involves the DDB1-CUL4A(VPRBP) E3 ubiquitin ligase. PLoS Pathog 3:e85. http://dx.doi.org/10.1371/journal.ppat.0030085
16. Hrecka K, Gierszewska M, Srivastava S, Kozaczkiewicz L, Swanson SK, Florens L, Washburn MP, Skowronski J. 2007. Lentiviral Vpr usurps Cul4-DDB1[VprBP] E3 ubiquitin ligase to modulate cell cycle. Proc Natl Acad Sci U S A 104:11778-11783. http://dx.doi.org/10.1073/pnas.0702102104
17. Cybulski KE, Howlett NG. 2011. FANCP/SLX4: a Swiss army knife of DNA interstrand crosslink repair. Cell Cycle 10:1757-1763. http://dx.doi.org/10.4161/cc.10.11.15818
18. Guervilly JH, Takedachi A, Naim V, Scaglione S, Chawhan C, Lovera Y, Despras E, Kuraoka I, Kannouche P, Rosselli F, Gaillard PH. 2015. The SLX4 complex is a SUMO E3 ligase that impacts on replication stress outcome and genome stability. Mol Cell 57:123-137. http://dx.doi.org/10.1016/j.molcel.2014.11.014
19. Ouyang J, Garner E, Hallet A, Nguyen HD, Rickman KA, Gill G, Smogorzewska A, Zou L. 2015. Noncovalent interactions with SUMO and ubiquitin orchestrate distinct functions of the SLX4 complex in genome maintenance. Mol Cell 57:108-122. http://dx.doi.org/10.1016/j.molcel.2014.11.015
20. Berger G, Lawrence M, Hué S, Neil SJ. 2015. G2/M cell cycle arrest correlates with primate lentiviral Vpr interaction with the SLX4 complex. J Virol 89:230-240. http://dx.doi.org/10.1128/JVI.02307-14
21. Duggal NK, Emerman M. 2012. Evolutionary conflicts between viruses and restriction factors shape immunity. Nat Rev Immunol 12:687-695. http://dx.doi.org/10.1038/nri3295
22. Fregoso OI, Ahn J, Wang C, Mehrens J, Skowronski J, Emerman M. 2013. Evolutionary toggling of Vpx/Vpr specificity results in divergent recognition of the restriction factor SAMHD1. PLoS Pathog 9:e1003496. http://dx.doi.org/10.1371/journal.ppat.1003496
23. Keele BF, Van Heuverswyn F, Li Y, Bailes E, Takehisa J, Santiago ML, Bibollet-Ruche F, Chen Y, Wain LV, Liegeois F, Loul S, Ngole EM, Bienvenue Y, Delaporte E, Brookfield JF, Sharp PM, Shaw GM, Peeters M, Hahn BH. 2006. Chimpanzee reservoirs of pandemic and nonpandemic HIV-1. Science 313:523-526. http://dx.doi.org/10.1126/science.1126531
24. Sharp PM, Hahn BH. 2011. Origins of HIV and the AIDS pandemic. Cold Spring Harb Perspect Med 1:a006841. http://dx.doi.org/10.1101/cshperspect.a006841
25. Bailes E, Gao F, Bibollet-Ruche F, Courgnaud V, Peeters M, Marx PA, Hahn BH, Sharp PM. 2003. Hybrid origin of SIV in chimpanzees. Science 300:1713. http://dx.doi.org/10.1126/science.1080657
26. Gao F, Yue L, White AT, Pappas PG, Barchue J, Hanson AP, Greene BM, Sharp PM, Shaw GM, Hahn BH. 1992. Human infection by genetically diverse SIVSM-related HIV-2 in west Africa. Nature 358:495-499. http://dx.doi.org/10.1038/358495a0
27. Santiago ML, Range F, Keele BF, Li Y, Bailes E, Bibollet-Ruche F, Fruteau C, Noë R, Peeters M, Brookfield JF, Shaw GM, Sharp PM, Hahn BH. 2005. Simian immunodeficiency virus infection in free-ranging sooty mangabeys (Cercocebus atys atys) from the Tai Forest, Côte d’Ivoire: implications for the origin of epidemic human immunodeficiency virus type 2. J Virol 79:12515-12527. http://dx.doi.org/10.1128/JVI.79.19.12515-12527.2005
28. Andreassen PR, D’Andrea AD, Taniguchi T. 2004. ATR couples FANCD2 monoubiquitination to the DNA-damage response. Genes Dev 18:1958-1963. http://dx.doi.org/10.1101/gad.1196104
29. Fletcher TM, 3rd, Brichacek B, Sharova N, Newman MA, Stivahtis G, Sharp PM, Emerman M, Hahn BH, Stevenson M. 1996. Nuclear import and cell cycle arrest functions of the HIV-1 Vpr protein are encoded by two separate genes in HIV-2/SIV(SM). EMBO J 15:6155-6165
30. Planelles V, Jowett JB, Li QX, Xie Y, Hahn B, Chen IS. 1996. Vprinduced cell cycle arrest is conserved among primate lentiviruses. J Virol 70:2516-2524
31. Muñoz IM, Hain K, Déclais AC, Gardiner M, Toh GW, Sanchez-Pulido L, Heuckmann JM, Toth R, Macartney T, Eppink B, Kanaar R, Ponting CP, Lilley DM, Rouse J. 2009. Coordination of structure-specific nucleases by human SLX4/BTBD12 is required for DNA repair. Mol Cell 35:116-127. http://dx.doi.org/10.1016/j.molcel.2009.06.020
32. Svendsen JM, Smogorzewska A, Sowa ME, O’Connell BC, Gygi SP, Elledge SJ, Harper JW. 2009. Mammalian BTBD12/SLX4 assembles a Holliday junction resolvase and is required for DNA repair. Cell 138: 63-77. http://dx.doi.org/10.1016/j.cell.2009.06.030
33. DePaula-Silva AB, Cassiday PA, Chumley J, Bosque A, Monteiro-Filho CM, Mahon CS, Cone KR, Krogan N, Elde NC, Planelles V. 2015. Determinants for degradation of SAMHD1, Mus81 and induction of G2 arrest in HIV-1 Vpr and SIVagm Vpr. Virology 477:10-17. http://dx.doi.org/10.1016/j.virol.2014.12.040
34. Zhou X, DeLucia M, Ahn J. 2016. SLX4/SLX1 independent downregulation of MUS81/EME1 by HIV-1 Vpr. J Biol Chem 291:16936-16947. http://dx.doi.org/10.1074/jbc.M116.721183
35. Hrecka K, Hao C, Shun MC, Kaur S, Swanson SK, Florens L, Washburn MP, Skowronski J. 2016. HIV-1 and HIV-2 exhibit divergent interactions with HLTF and UNG2 DNA repair proteins. Proc Natl Acad Sci U S A 113:E3921-E3930. http://dx.doi.org/10.1073/pnas.1605023113
36. Compton AA, Hirsch VM, Emerman M. 2012. The host restriction factor APOBEC3G and retroviral Vif protein coevolve due to ongoing genetic conflict. Cell Host Microbe 11:91-98. http://dx.doi.org/10.1016/j.chom.2011.11.010
37. Mariani R, Chen D, Schröfelbauer B, Navarro F, König R, Bollman B, Münk C, Nymark-McMahon H, Landau NR. 2003. Species-specific exclusion of APOBEC3G from HIV-1 virions by Vif. Cell 114:21-31. http://dx.doi.org/10.1016/S0092-8674(03)00515-4
38. Stivahtis GL, Soares MA, Vodicka MA, Hahn BH, Emerman M. 1997. Conservation and host specificity of Vpr-mediated cell cycle arrest suggest a fundamental role in primate lentivirus evolution and biology. J Virol 71:4331-4338
39. Rosa A, Chande A, Ziglio S, De Sanctis V, Bertorelli R, Goh SL, McCauley SM, Nowosielska A, Antonarakis SE, Luban J, Santoni FA, Pizzato M. 2015. HIV-1 Nef promotes infection by excluding SERINC5 from virion incorporation. Nature 526:212-217. http://dx.doi.org/10.1038/nature15399
40. Usami Y, Wu Y, Göttlinger HG. 2015. SERINC3 and SERINC5 restrict HIV-1 infectivity and are counteracted by Nef. Nature 526:218-223. http://dx.doi.org/10.1038/nature15400
41. Murrell I, Vollbrecht T, Guatelli J, Wertheim JO. 2016. The evolutionary histories of antiretroviral proteins SERINC3 and SERINC5 do not support an evolutionary arms race in primates. J Virol 90:8085-8089. http://dx.doi.org/10.1128/JVI.00972-16
42. Schröfelbauer B, Yu Q, Zeitlin SG, Landau NR. 2005. Human immunodeficiency virus type 1 Vpr induces the degradation of the UNG and SMUG uracil-DNA glycosylases. J Virol 79:10978-10987. http://dx.doi.org/10.1128/JVI.79.17.10978-10987.2005
43. Lahouassa H, Blondot ML, Chauveau L, Chougui G, Morel M, Leduc M, Guillonneau F, Ramirez BC, Schwartz O, Margottin-Goguet F. 2016. HIV-1 Vpr degrades the HLTF DNA translocase in T cells and macrophages. Proc Natl Acad Sci U S A 113:5311-5316. http://dx.doi.org/10.1073/pnas.1600485113
44. Lee J, Zhou P. 2007. DCAFs, the missing link of the CUL4-DDB1 ubiquitin ligase. Mol Cell 26:775-780. http://dx.doi.org/10.1016/j.molcel.2007.06.001
45. Kim K, Heo K, Choi J, Jackson S, Kim H, Xiong Y, An W. 2012. Vpr-binding protein antagonizes p53-mediated transcription via direct interaction with H3 tail. Mol Cell Biol 32:783-796. http://dx.doi.org/10.1128/MCB.06037-11
46. Kim K, Kim JM, Kim JS, Choi J, Lee YS, Neamati N, Song JS, Heo K, An W. 2013. VprBP has intrinsic kinase activity targeting histone H2A and represses gene transcription. Mol Cell 52:459-467. http://dx.doi.org/10.1016/j.molcel.2013.09.017
47. McCall CM, Miliani de Marval PL, Chastain PD, 2nd, Jackson SC, He YJ, Kotake Y, Cook JG, Xiong Y. 2008. Human immunodeficiency virus type 1 Vpr-binding protein VprBP, a WD40 protein associated with the DDB1CUL4 E3 ubiquitin ligase, is essential for DNA replication and embryonic development. Mol Cell Biol 28:5621-5633. http://dx.doi.org/10.1128/MCB.00232-08
48. Aubert M, Boyle NM, Stone D, Stensland L, Huang ML, Magaret AS, Galetto R, Rawlings DJ, Scharenberg AM, Jerome KR. 2014. In vitro inactivation of latent HSV by targeted mutagenesis using an HSV-specific homing endonuclease. Mol Ther Nucleic Acids 3:e146. http://dx.doi.org/10.1038/mtna.2013.75
49. Sanjana NE, Shalem O, Zhang F. 2014. Improved vectors and genomewide libraries for CRISPR screening. Nat Methods 11:783-784. http://dx.doi.org/10.1038/nmeth.3047
50. Choi VW, Asokan A, Haberman RA, Samulski RJ. 2007. Production of recombinant adeno-associated viral vectors for in vitro and in vivo use. Curr Protoc Mol Biol 78(III):16.25:16.25.1-16.25.24. http://dx.doi.org/10.1002/0471142727.mb1625s78
51. Aurnhammer C, Haase M, Muether N, Hausl M, Rauschhuber C, Huber I, Nitschko H, Busch U, Sing A, Ehrhardt A, Baiker A. 2012. Universal real-time PCR for the detection and quantification of adenoassociated virus serotype 2-derived inverted terminal repeat sequences. Hum Gene Ther Methods 23:18-28. http://dx.doi.org/10.1089/hgtb.2011.034
52. Castella M, Jacquemont C, Thompson EL, Yeo JE, Cheung RS, Huang JW, Sobeck A, Hendrickson EA, Taniguchi T. 2015. FANCI regulates recruitment of the FA Core complex at sites of DNA damage independently of FANCD2. PLoS Genet 11:e1005563. http://dx.doi.org/10.1371/journal.pgen.1005563